Ventricular Assist Devices Market Segmentation:
Type Segment Analysis
The continuous flow VADs segment is anticipated to lead the market, garnering 56% of the share by 2037. The growth of the ventricular assist devices market can be attributed to the technological advancements that have enhanced the survival rates of patients and lowered the risk factors. For example, the HeartMate 3 has been approved by the FDA to lower the rates of stroke in comparison with the pump thrombosis. The widespread adoption of the flow VADs is further aided by Medicare’s National Coverage Determination, which has expanded the eligibility criteria. The fully magnetically levitated pumps cause no clotting and have zero friction.
End User Segment Analysis
The hospital's segment is anticipated to garner a share of 63.2% by the end of 2037, owing to the rising need for post-operative care and intensive management of infections. The Centers for Medicare & Medicaid Services (CMS) mandates that the implementation of the VAD be conducted in hospitals accredited by the Joint Commission. Moreover, the Centers for Disease Control and Prevention focus on the hospital-based infection surveillance protocols as necessary for long-term outcomes. Also, the hospitals are primary VAD implant centers, with 91% of the procedures performed in cardiac specialty units.
Our in-depth analysis of the global ventricular assist devices market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Design |
|
|
Application |
|
|
End user |
|
|
Age Group |
|
